Abstract
Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have